The Effectiveness and Cost-Effectiveness of Hepatitis C Screening for Migrants in the EU/EEA: A Systematic Review

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
hepatitis B 1 infectiousdiseases
hepatitis C 10 infectiousdiseases
ribavirin 5 infectiousdiseasesdrugs
ritonavir 1 infectiousdiseasesdrugs

Graph of close proximity drug and disease terms (within 200 characters).

Note: If this graph is empty, then there are no terms that meet the proximity constraint.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
ribavirin 16444 Kimer et al., the risk of HCC was lower in those on antiviral HCV therapy (IFN or PEG-IFN alone or with ribavirin ) compared to placebo or no intervention (RR = 0.53, 95% CI 0.34–0.81). This effect was much more pronounced
ribavirin 36220 ratio; NAT: nucleic acid test; OR: odds ratio; PEG-IFN: pegylated interferon; PR: pegylated-interferon- ribavirin ; RBV: ribavirin; RCT: randomized controlled trial; RIBA: recombinant immunoblot assay; RNA: ribonucleic
ribavirin 36236 acid test; OR: odds ratio; PEG-IFN: pegylated interferon; PR: pegylated-interferon-ribavirin; RBV: ribavirin ; RCT: randomized controlled trial; RIBA: recombinant immunoblot assay; RNA: ribonucleic acid; RR: risk
ribavirin 56616 ledipasvir; OBV: ombitasvir; PI: protease inhibitor; PEG-IFN: pegylated interferon; PR: pegylated-interferon- ribavirin ; PSA: probabilistic sensitivity analysis; PTV-r: paritaprevir-ritonavir; QALY: quality-adjusted life
ribavirin 56739 probabilistic sensitivity analysis; PTV-r: paritaprevir-ritonavir; QALY: quality-adjusted life years; RBV: ribavirin ; RNA: ribonucleic acid; SIM: simeprevir; SOF: sofosbuvir; SVR: sustained virological response; TEL/TVR:
ritonavir 56688 interferon; PR: pegylated-interferon-ribavirin; PSA: probabilistic sensitivity analysis; PTV-r: paritaprevir- ritonavir ; QALY: quality-adjusted life years; RBV: ribavirin; RNA: ribonucleic acid; SIM: simeprevir; SOF: sofosbuvir;
Select Disease Character Offset Disease Term Instance
hepatitis B 56334 DAA: direct acting antiviral; DAV: dasabuvir; DCV: daclatasvir; F: fibrosis stage; G: genotype; HBV: hepatitis B virus; HCV: hepatitis C virus; HIV: human immunodeficiency virus; ICER: incremental cost-effectiveness
hepatitis C 2363 francesco.castelli@unibs.itPublication date (epub): 9/2018Publication date (ppub): 9/2018AbstractChronic hepatitis C (HCV) is a public health priority in the European Union/European Economic Area (EU/EEA) and is a leading
hepatitis C 3688 possible in the region if health systems include and treat migrants for HCV.1. IntroductionChronic hepatitis C is an important public health problem in the EU/EEA, with an estimated 3.24 million persons having active
hepatitis C 3806 important public health problem in the EU/EEA, with an estimated 3.24 million persons having active hepatitis C virus (HCV) infection [[1],[2]]. It is a leading cause of chronic liver disease and liver cancer in
hepatitis C 9430 publications between 1 January 2010 and 12 May 2016. A combination of key terms was used including “ hepatitis C /HCV”, “screening”, “migrants”, “costs”, “cost-effectiveness” AND “guidelines”,
hepatitis C 9924 and WHO. We applied no language restrictions to the search. In the second search, using terms of “ hepatitis C /HCV”, “screening”, “costs”, and “cost-effectiveness”, Medline via Ovid, EMBASE, the NHS
hepatitis C 29862 Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) diagram for the effectiveness of hepatitis C screening.Figure 2PRISMA diagram for the resource use, costs, and cost-effectiveness for hepatitis C
hepatitis C 29963 hepatitis C screening.Figure 2PRISMA diagram for the resource use, costs, and cost-effectiveness for hepatitis C screening.ijerph-15-02013-t001_Table 1Table 1Characteristics of studies on the effectiveness of hepatitis
hepatitis C 30071 hepatitis C screening.ijerph-15-02013-t001_Table 1Table 1Characteristics of studies on the effectiveness of hepatitis C screening.StudyQuality of Systematic Review/GRADE Certainty of EvidenceDesignPopulationIntervention/OutcomesResultsKhuroo2015
hepatitis C 35993 grading of recommendation assessment, development and evaluation; HCC: hepatocellular carcinoma; HCV: hepatitis C virus; HIV: human immunodeficiency virus; HR: hazard ratio; IFN: interferon; IR: incidence rate; LR:
hepatitis C 56358 antiviral; DAV: dasabuvir; DCV: daclatasvir; F: fibrosis stage; G: genotype; HBV: hepatitis B virus; HCV: hepatitis C virus; HIV: human immunodeficiency virus; ICER: incremental cost-effectiveness ratio; IFN: interferon;

You must be authorized to submit a review.